Concepedia

Author

Avital Lev

Fox Chase Cancer CenterORCID

Also Known As

A Lev, Avital Lev, Lev, Avital

55

Publications

725

Citations

13

H-Index

21

Concepts

All Affiliations

Fox Chase Cancer CenterLifespanBrown UniversityOncoceutics (United States)Massachusetts General Hospital
AL

About

Avital Lev is an author at Fox Chase Cancer Center specializing in medicine, tumor biology, and radiation oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

4

4

153

2

Cell Biology

3

3

137

3

Pharmacology

3

3

109

4

Health Sciences

1

1

44

5

Pathology

1

1

16

Avital Lev

×

12

Publications

538

Citations

12

H-Index

YearCitations

Application of 3D tumoroid systems to define immune and cytotoxic therapeutic responses based on tumoroid and tissue slice culture molecular signatures

Niklas K. Finnberg, Prashanth Gokare, Avital Lev,

Oncotarget

2017

126

Preclinical evaluation of the imipridone family, analogs of clinical stage anti-cancer small molecule ONC201, reveals potent anti-cancer effects of ONC212

Jessica Wagner, C. Leah B. Kline, Marie D. Ralff,

Cell Cycle

2017

79

miR-6883 Family miRNAs Target CDK4/6 to Induce G1 Phase Cell-Cycle Arrest in Colon Cancer Cells

Amriti R. Lulla, Michael Slifker, Yan Zhou,

Cancer Research

2017

54

Anti-pancreatic cancer activity of ONC212 involves the unfolded protein response (UPR) and is reduced by IGF1-R and GRP78/BIP

Avital Lev, Amriti R. Lulla, Jessica Wagner,

Oncotarget

2017

48

Cancer stem cell-related gene expression as a potential biomarker of response for first-in-class imipridone ONC201 in solid tumors

Varun V. Prabhu, Amriti R. Lulla, Neel S. Madhukar,

PLoS ONE

2017

44

ONC201 Targets AR and AR-V7 Signaling, Reduces PSA, and Synergizes with Everolimus in Prostate Cancer

Avital Lev, Amriti R. Lulla, Brian C. Ross,

Molecular Cancer Research

2018

43

BRCA2, EGFR, and NTRK mutations in mismatch repair-deficient colorectal cancers with MSH2 or MLH1 mutations

Safoora Deihimi, Avital Lev, Michael Slifker,

Oncotarget

2017

34

P53-independent partial restoration of the p53 pathway in tumors with mutated p53 through ATF4 transcriptional modulation by ERK1/2 and CDK9

Xiaobing Tian, Nagib Ahsan, Amriti R. Lulla,

Neoplasia

2021

27

Anti-cancer efficacy including Rb-deficient tumors and VHL-independent HIF1α proteasomal destabilization by dual targeting of CDK1 or CDK4/6 and HSP90

Shuai Zhao, Lanlan Zhou, David T. Dicker,

Scientific Reports

2021

27

TRAIL receptor agonists convert the response of breast cancer cells to ONC201 from anti-proliferative to apoptotic

Marie D. Ralff, Aakash Jhaveri, Jocelyn E. Ray,

Oncotarget

2020

26

Page 1